187 related articles for article (PubMed ID: 15337448)
21. Synthesis, enzymatic activity, and X-ray crystallography of an unusual class of amino acids.
Chen W; Kuntz DA; Hamlet T; Sim L; Rose DR; Mario Pinto B
Bioorg Med Chem; 2006 Dec; 14(24):8332-40. PubMed ID: 17010621
[TBL] [Abstract][Full Text] [Related]
22. Synthesis and glycosidase inhibitory activities of chain-modified analogues of the glycosidase inhibitors salacinol and blintol.
Nasi R; Sim L; Rose DR; Pinto BM
Carbohydr Res; 2007 Sep; 342(12-13):1888-94. PubMed ID: 17359953
[TBL] [Abstract][Full Text] [Related]
23. Antimycobacterial activity of UDP-galactopyranose mutase inhibitors.
Borrelli S; Zandberg WF; Mohan S; Ko M; Martinez-Gutierrez F; Partha SK; Sanders DA; Av-Gay Y; Pinto BM
Int J Antimicrob Agents; 2010 Oct; 36(4):364-8. PubMed ID: 20678902
[TBL] [Abstract][Full Text] [Related]
24. Enzymatic synthesis of UDP-galactofuranose and an assay for UDP-galactopyranose mutase based on high-performance liquid chromatography.
Lee R; Monsey D; Weston A; Duncan K; Rithner C; McNeil M
Anal Biochem; 1996 Nov; 242(1):1-7. PubMed ID: 8923956
[TBL] [Abstract][Full Text] [Related]
25. Synthesis of analogues of salacinol containing a carboxylate inner salt and their inhibitory activities against human maltase glucoamylase.
Chen W; Sim L; Rose DR; Pinto BM
Carbohydr Res; 2007 Sep; 342(12-13):1661-7. PubMed ID: 17597595
[TBL] [Abstract][Full Text] [Related]
26. Potent ligands for prokaryotic UDP-galactopyranose mutase that exploit an enzyme subsite.
Dykhuizen EC; Kiessling LL
Org Lett; 2009 Jan; 11(1):193-6. PubMed ID: 19067595
[TBL] [Abstract][Full Text] [Related]
27. Synthesis of 2-amido, 2-amino, and 2-azido derivatives of the nitrogen analogue of the naturally occurring glycosidase inhibitor salacinol and their inhibitory activities against O-GlcNAcase and NagZ enzymes.
Choubdar N; Bhat RG; Stubbs KA; Yuzwa S; Pinto BM
Carbohydr Res; 2008 Jul; 343(10-11):1766-77. PubMed ID: 18358456
[TBL] [Abstract][Full Text] [Related]
28. Synthesis of nitrogen analogues of salacinol and their evaluation as glycosidase inhibitors.
Ghavami A; Johnston BD; Jensen MT; Svensson B; Pinto BM
J Am Chem Soc; 2001 Jul; 123(26):6268-71. PubMed ID: 11427050
[TBL] [Abstract][Full Text] [Related]
29. Identification of inhibitors for UDP-galactopyranose mutase.
Soltero-Higgin M; Carlson EE; Phillips JH; Kiessling LL
J Am Chem Soc; 2004 Sep; 126(34):10532-3. PubMed ID: 15327298
[TBL] [Abstract][Full Text] [Related]
30. Reversible and efficient inhibition of UDP-galactopyranose mutase by electrophilic, constrained and unsaturated UDP-galactitol analogues.
Ansiaux C; N'Go I; Vincent SP
Chemistry; 2012 Nov; 18(46):14860-6. PubMed ID: 23015271
[TBL] [Abstract][Full Text] [Related]
31. Identification and partial characterization of two eukaryotic UDP-galactopyranose mutases.
Bakker H; Kleczka B; Gerardy-Schahn R; Routier FH
Biol Chem; 2005 Jul; 386(7):657-61. PubMed ID: 16207086
[TBL] [Abstract][Full Text] [Related]
32. Structural basis of ligand binding to UDP-galactopyranose mutase from Mycobacterium tuberculosis using substrate and tetrafluorinated substrate analogues.
van Straaten KE; Kuttiyatveetil JR; Sevrain CM; Villaume SA; Jiménez-Barbero J; Linclau B; Vincent SP; Sanders DA
J Am Chem Soc; 2015 Jan; 137(3):1230-44. PubMed ID: 25562380
[TBL] [Abstract][Full Text] [Related]
33. Synthesis and inhibition properties of conformational probes for the mutase-catalyzed UDP-galactopyranose/furanose interconversion.
Caravano A; Mengin-Lecreulx D; Brondello JM; Vincent SP; Sinaÿ P
Chemistry; 2003 Dec; 9(23):5888-98. PubMed ID: 14673861
[TBL] [Abstract][Full Text] [Related]
34. Drug targeting Mycobacterium tuberculosis cell wall synthesis: development of a microtiter plate-based screen for UDP-galactopyranose mutase and identification of an inhibitor from a uridine-based library.
Scherman MS; Winans KA; Stern RJ; Jones V; Bertozzi CR; McNeil MR
Antimicrob Agents Chemother; 2003 Jan; 47(1):378-82. PubMed ID: 12499218
[TBL] [Abstract][Full Text] [Related]
35. Site-directed mutagenesis of UDP-galactopyranose mutase reveals a critical role for the active-site, conserved arginine residues.
Chad JM; Sarathy KP; Gruber TD; Addala E; Kiessling LL; Sanders DA
Biochemistry; 2007 Jun; 46(23):6723-32. PubMed ID: 17511471
[TBL] [Abstract][Full Text] [Related]
36. Structural basis of substrate binding to UDP-galactopyranose mutase: crystal structures in the reduced and oxidized state complexed with UDP-galactopyranose and UDP.
Partha SK; van Straaten KE; Sanders DA
J Mol Biol; 2009 Dec; 394(5):864-77. PubMed ID: 19836401
[TBL] [Abstract][Full Text] [Related]
37. Combined molecular dynamics, STD-NMR, and CORCEMA protocol yields structural model for a UDP-galactopyranose mutase-inhibitor complex.
Shi Y; Ardá A; Pinto BM
Bioorg Med Chem Lett; 2015 Mar; 25(6):1284-7. PubMed ID: 25681227
[TBL] [Abstract][Full Text] [Related]
38. UDP-galactopyranose mutase has a novel structure and mechanism.
Sanders DA; Staines AG; McMahon SA; McNeil MR; Whitfield C; Naismith JH
Nat Struct Biol; 2001 Oct; 8(10):858-63. PubMed ID: 11573090
[TBL] [Abstract][Full Text] [Related]
39. Potentiometric analysis of UDP-galactopyranose mutase: stabilization of the flavosemiquinone by substrate.
Fullerton SW; Daff S; Sanders DA; Ingledew WJ; Whitfield C; Chapman SK; Naismith JH
Biochemistry; 2003 Feb; 42(7):2104-9. PubMed ID: 12590598
[TBL] [Abstract][Full Text] [Related]
40. Galactofuranose biosynthesis in Escherichia coli K-12: identification and cloning of UDP-galactopyranose mutase.
Nassau PM; Martin SL; Brown RE; Weston A; Monsey D; McNeil MR; Duncan K
J Bacteriol; 1996 Feb; 178(4):1047-52. PubMed ID: 8576037
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
